Does the addition of recLH (Luveris [lutropin alfa]) to a regimen of recFSH (Gonal-F [follitropin alfa]) and GnRH antagonist (Cetrotide [cetrorelix]) improve ovarian response and implantation rates in patients age greater than 35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?

Trial Profile

Does the addition of recLH (Luveris [lutropin alfa]) to a regimen of recFSH (Gonal-F [follitropin alfa]) and GnRH antagonist (Cetrotide [cetrorelix]) improve ovarian response and implantation rates in patients age greater than 35 years undergoing in vitro fertilisation (IVF)/embryo transfer (ET)?

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2010

At a glance

  • Drugs Lutropin alfa (Primary) ; Cetrorelix; Follitropin alfa
  • Indications Female infertility
  • Focus Therapeutic Use
  • Acronyms Luveris study
  • Most Recent Events

    • 01 Jan 2010 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
    • 25 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top